Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance

22 Jul 2025

Abstract excerpt

Therapeutic responses to identical chemotherapy regimens often vary significantly among patients with the same type of cancer, underscoring the need for additional biomarkers to identify individuals most likely to benefit from specific treatments. The expression of SLFN11 (Schlafen11) has been identified as a potential biomarker for predicting patient responses to DNA-damaging agents and PARP inhibitors, as it...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to PARP inhibition in cancer therapy

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 40766331
DOI: 10.3389/fonc.2025.1582738

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidancePMID 40766331Read ↗

SLFN11 is a general target for enhancing the sensitivity of cancer to chemotherapy (DNA-damaging agents)Semantic proximity Read ↗

SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in ovarian cancerSemantic proximity Read ↗

The crucial role of single-stranded DNA binding in enhancing sensitivity to DNA-damaging agents for Schlafen 11 and Schlafen 13Semantic proximity Read ↗

Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapySemantic proximity Read ↗

SLFN11 Enhances Cisplatin Sensitivity in Pediatric Cancer via Activation of Stress-Response and Suppression of Survival PathwaysSemantic proximity Read ↗

Structural, molecular, and functional insights into Schlafen proteinsSemantic proximity Read ↗

Interrogation of SLFN11 in pediatric sarcomas uncovers an unexpected biological role and a novel therapeutic approach to overcoming resistance to replicative stressSemantic proximity Read ↗

Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agentsSemantic proximity Read ↗

Immunohistochemical analysis of SLFN11 expression uncovers potential non-responders to DNA-damaging agents overlooked by tissue RNA-seqSemantic proximity Read ↗

Methylation of SLFN11 is a Marker of Poor Prognosis and Cisplatin Resistance in Colorectal CancerSemantic proximity Read ↗

Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugsSemantic proximity Read ↗

Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.